1. Home
  2. SINT vs BLRX Comparison

SINT vs BLRX Comparison

Compare SINT & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SiNtx Technologies Inc.

SINT

SiNtx Technologies Inc.

HOLD

Current Price

$2.45

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.83

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SINT
BLRX
Founded
1996
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
12.6M
IPO Year
2007
2010

Fundamental Metrics

Financial Performance
Metric
SINT
BLRX
Price
$2.45
$2.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
2
Target Price
$11.00
$19.00
AVG Volume (30 Days)
29.8K
18.9K
Earning Date
05-13-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
59.45
N/A
EPS
N/A
N/A
Revenue
$1,018,000.00
N/A
Revenue This Year
$30.26
N/A
Revenue Next Year
$413.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$2.15
52 Week High
$6.78
$7.77

Technical Indicators

Market Signals
Indicator
SINT
BLRX
Relative Strength Index (RSI) 49.11 61.30
Support Level $2.30 $2.66
Resistance Level $2.97 $3.11
Average True Range (ATR) 0.21 0.20
MACD -0.04 0.08
Stochastic Oscillator 50.99 64.98

Price Performance

Historical Comparison
SINT
BLRX

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: